News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …
Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a "Moderate …
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of the company's stock for $524,625 under a pre-arranged Rule 10b5-1 plan, reducing his position by 9.36%. The company's stock rose 3.7% to $24.63, and it reported a quarterly loss of $0.82 per share, matching …
Bicara Therapeutics Inc.'s Chief Financial Officer, Hyep Ivan, exercised stock options for 12,500 shares at $3.7898 per share and simultaneously sold these shares at a weighted average price of $27.9673 per share. These transactions, executed on August 10, 2026, were conducted under a Rule …
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp exercised 18,750 stock options at $3.7898 per share and simultaneously sold 18,750 common shares at a weighted average price of $27.9751. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 31, 2026. …
An insider at Bicara Therapeutics sold shares valued at $524,533, as per a recent SEC filing. This transaction is one of several insider sales reported for the company around the same date, alongside other corporate news including earnings reports and analyst rating adjustments.
Bicara Therapeutics Inc. reported better-than-expected Q2 losses of 82 cents per share, surpassing analyst estimates. Following the earnings, BTIG and Wells Fargo analysts adjusted their price targets for BCAX, with BTIG maintaining a "Buy" rating and raising its price target from $28 to $39, …
Mizuho increased its price target for Bicara Therapeutics (NASDAQ:BCAX) to $20 from $18, citing improved positioning of its ficera drug candidate for head and neck squamous cell carcinoma. The company reported Q2 2026 earnings, updated its pipeline, and announced executive leadership changes. Bicara anticipates …
Bicara Therapeutics announced its second-quarter 2026 financial results and significant leadership transitions, including Ryan Cohlhepp becoming President & CEO in January 2027. The company is on track for substantial enrollment in its pivotal FORTIFI-HN01 study by year-end, with topline results expected mid-2027, and reported …
(RTTNews) - Bicara Therapeutics Inc. (BCAX), a clinical-stage biopharmaceutical company, announced financial results for the second quarter reflecting a wider net loss. In addition, the company announced a few management changes and provided an update on its lead investigational asset, ficerafusp alfa. Bicara Therapeutics …
Bicara Therapeutics (BCAX) reported a net loss of $55.4 million for Q2 2026 and $111.6 million for the first half of 2026, primarily due to increased R&D and administrative expenses. Despite the larger loss, the clinical-stage oncology company holds a strong cash position of …
Morgan Stanley has increased its price target for Bicara Therapeutics (NASDAQ:BCAX) from $37 to $39, maintaining an Overweight rating due to the company's strong cash position. Bicara reported $497.3 million in cash and equivalents, projected to fund operations into the first half of 2029, …
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Moby Executive Narrative Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …
Key Points Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. FICERA's pivotal FORTIFI-HN01 trial remains on track for substantial enrollment by the end of 2026, with an interim analysis planned for mid-2027. Bicara highlighted three-year data suggesting roughly one-third of …
Bicara Therapeutics Inc. (BCAX) reported a narrower-than-expected loss of $0.82 per share for Q2 2026, surpassing Wall Street's estimate of a $0.85 loss. Despite this, the company's net loss widened to $55.4M as it continues significant investments in its clinical development programs for bifunctional …
Key Points Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. FICERA's pivotal FORTIFI-HN01 trial remains on track for substantial enrollment by the end of 2026, with an interim analysis planned for mid-2027. Bicara highlighted three-year data suggesting roughly one-third of …
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on innovative cancer treatments, particularly bifunctional therapies for solid tumors. Despite operating at a loss, which is common for early-stage biotech firms, analysts project a 14.36% upside for the stock, driven by its promising …
Search by ticker symbol or company name and select a result to open its chart.